Close up of someone's feet as they walk in active wear.

StraxCorp aims to change this reality. Its mission is to identify bone decay early.

Improving the diagnosis of bone decay


Osteoporosis is a silent disease which reduces the density and quality of bone. Sufferers can be unaware they have a problem until they experience a fracture, which can be painful, traumatic and life-changing.

It's a preventable disease with diet, exercise and drug therapies available, but it is under-diagnosed.

Even established bone mineral density tests are failing to pick up a large proportion of those at risk of fractures, which means the number of fractures is steadily rising.

The medtech start-up, StraxCorp, wants to change this reality. Its mission is to identify bone decay early so sufferers can get onto preventative treatment.

Its new diagnostic technology provides sophisticated bone analysis data from simple CT wrist scans.

Based in Melbourne, StraxCorp and its technology grew out of the University of Melbourne, with Doctors Roger Zebaze and Ego Seeman inventing the technology and founding the company.

In 2012, on the strength of an Australian Government commercialisation grant, the company brought in current executive chair, Greg Brown, to help design, develop and commercialise the technology into a legally marketed medical device.

Brown says the government's commercialisation grant and accompanying expert advice has been critical as the company moves to verify the performance of its technology and build awareness of it amongst CT scanning and pharmaceutical companies.

This technology is important to the world and without the government funding it would not be getting to the market.

Greg Brown, Executive Chairman, StraxCorp

The StraxCorp technology examines, in three dimensions, the decay of the micro–architecture of the bone, which can identify early signs of bone decay and measure the impact of drug therapies.

"The new technology can pick up the 40 per cent of osteopenia patients and the 10 per cent of ‘normal' patients who are likely to have osteoporotic fractures, but are currently not being identified through bone mineral density tests," Brown says.

"This will lead to big improvements in early detection and prevention, as more at risk patients will be accessing treatments such as anti-resorptive drug therapy."

The StraxCorp technology can also help identify which therapies are suitable for an individual sufferer.